Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force.
Hiromu TanakaShotaro ChubachiHo NamkoongYasunori SatoTakanori AsakuraHo LeeShuhei AzekawaShiro OtakeKensuke NakagawaraTakahiro FukushimaMayuko WataseKaori SakuraiTatsuya KusumotoYasushi KondoKatsunori MasakiHirofumi KamataMakoto IshiiYuko KanekoNaoki HasegawaSoichiro UedaMamoru SasakiTakehiro IzumoMinoru InomataNaoki MiyazawaYasuhiro KimuraYusuke SuzukiNorihiro HaradaMasako IchikawaTohru TakataHiroyasu IshikuraTakashi YoshiyamaHiroyuki KokutoKoji MurakamiHirohito SanoTetsuya UedaNaota KuwaharaAkiko FujiwaraTakashi OguraTakashi InoueTakahiro AsamiYoshikazu MutohIchiro NakachiRie BabaKoichi NishiMayuko TaniJunko KagyoMizuha HashiguchiTsuyoshi OgumaKoichiro AsanoMasanori NishikawaHiroki WatanabeYukinori OkadaRyuji KoikeYuko KitagawaAkinori KimuraSeiya ImotoSatoru MiyanoSeishi OgawaTakanori KanaiKoichi FukunagaPublished in: Open forum infectious diseases (2023)
Baricitinib is effective at preventing the need for invasive mechanical ventilation in patients with COVID-19.